Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 11 April 2019
    HitGen and Kaken Enter Into License Agreement
    Chengdu, China, April 11, 2019 HitGen Inc. announced today that HitGen Inc. and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing over 400 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds. A number of novel small molecule leads for an undisclosed target nominated by Kaken were the subject of this license agreement.
  • 25 March 2019
    HitGen and Almirall Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
    Chengdu, China, March 25, 2019, HitGen Ltd announced that the company has entered into a research collaboration with Almirall to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Almirall. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Almirall. Specific financial details were not disclosed.
  • 13 March 2019
    HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
    CHENGDU and MUMBAI –March 13, 2019,HitGenLtd. and Sun Pharma Advanced Research Company Ltd. (SPARC)(Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) todayannounced a research collaboration toidentifynovel small molecule leads for targets of interest.Under this collaboration,HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads forSPARC. Under the terms of the agreement,HitGenwill receive upfrontpaymentand will be eligible for certainmilestone payments.
  • 20 December 2018
    HitGen and Bayer Enter DNA-Encoded Library Based Research Collaboration
    Chengdu, China, December 20, 2018, HitGen Ltd announced that the company has entered into a research collaboration with the Crop Science division of Bayer to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for Bayer research endeavours. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments from Bayer. Specific financial details were not disclosed.
  • 11 December 2018
    HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
    Chengdu, China, December 11, 2018, HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (President and CEO: Masayuki Mitsuka; Headquarters: Osaka; “MTPC”) to identify novel small molecule leads for targets of interest. According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis, and screening system, to discover novel lead compounds. The collaboration will use HitGen’s libraries containing more than 300 billion individually DNA-encoded compounds. The DNA encoding of molecules enables screening and analysis of vast chemical space, supporting MTPC’s aim to increase success rates for the generation of target leads for new drugs and to drastically shorten screening timelines for expanding MTPC’s pipeline. Under the terms of the agreement, HitGen will receive technology access and research support payments, and be eligible for milestone payments from MTPC. Financial details were not disclosed.
  • 03 December 2018
    HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Genentech
    Chengdu, China,December 3rd, 2018 -HitGen Ltd today announced that it has entered into a drug discovery research collaboration withGenentech, a member of the Roche Group,to identify potential small molecule leads against targets of interest to Genentech. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments fromGenentech.
  • 21 November 2018
    HitGen and Biogen enter a DNA-Encoded Library-Based Drug Discovery Research Collaboration
    Chengdu, China, November 21, 2018, HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Biogen to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads which will be licensed exclusively to Biogen. Under the terms of the agreement, HitGen will receive upfront payments, and be eligible for milestone payments. Specific financial details were not disclosed.
  • 04 September 2018
    Seminar | Advancing Drug R&D Industry by Chemistry Development
    Topic: Translational Chemistry, Speaker: Phil S. Baran, Professor of Chemistry, The Scripps Research Institute Topic: Enantioselective and Remote C–H Activation Reactions, Speaker: Jin-Quan Yu, Department of Chemistry, The Scripps Research Institute
  • 22 August 2018
    SEMINAR | Development of selective irreversible BTK inhibitor
    Bruton’s tyrosine kinase (BTK) is a member of the Tec tyrosine kinase family, which is expressed in most hematopoietic cells such as B cells, myeloid cell, mast cells, and macrophage. BTK is a kinase that plays a crucial role in B-cell signaling pathway, which is an important downstream mediator of NF-κB and MAPK signaling pathways, which are strongly associated with cancer. Therefore, BTK is a promising biological target for therapeutic intervention of autoimmune diseases and cancer/B cell malignancies.
  • 16 August 2018
    HitGen Announces Innovative Drug Discovery Research Collaboration with LG Chem by Applying DNA-Encoded Technology
    Chengdu, China, August 17, 2018, HitGen Ltd today announced a multi-year major drug discovery research collaboration with LG Chem to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis, and screening system, to discover such novel leads. Under the terms of the agreement, HitGen will receive technology access and research support payments, and be eligible for milestone payments for multiple targets. Financial details were not disclosed.

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information